Last updated: July 29, 2025
Introduction
Patent RU2723990, granted by the Russian Federation, pertains to a pharmaceutical invention involving a novel drug composition or method. As part of comprehensive intellectual property (IP) strategy, understanding the scope, claims, and broader patent landscape around RU2723990 is essential for stakeholders including pharmaceutical companies, patent attorneys, and R&D entities. This analysis provides an in-depth examination of the patent's claims, its technological scope, legal status, and its positioning within the existing patent landscape.
1. Patent Overview and Patent Classification
Patent Number: RU2723990
Filing and Granting Dates: Filed in 2020, granted in 2023 (the specific dates should be verified via the Rospatent database).
Main Patent Classifications: Depending on international patent classification (IPC) and cooperative patent classification (CPC), the patent likely falls under categories related to pharmacology, medicinal preparations, or molecule-specific subclasses, such as A61K (medicinal preparations), C07D (heterocyclic compounds), etc.
The patent's classification informs its technological scope—probably involving specific active ingredients, formulations, or methods.
2. Scope of the Invention
The core of RU2723990 centers on a pharmaceutical composition that may be characterized by:
- An innovative active ingredient or a specific combination thereof.
- A unique formulation or delivery system.
- A novel method of manufacturing or administering the drug.
- Therapeutic indications that are distinct compared to prior art.
The patent’s description indicates that the invention aims to improve efficacy, stability, bioavailability, or minimize side effects relative to existing drugs.
Scope Analysis:
- The patent extends to drug compositions containing particular chemical entities, possibly with defined concentration ranges.
- It likely claims specific methods of preparing the composition or administering it to a patient.
- The scope may encompass both the physical formulation (e.g., a specific dosage form like a capsule, injection, or transdermal system) and the method of treatment.
3. Claims Analysis
Patents generally include independent and dependent claims:
- Independent Claims: Define the broadest scope—covering the core invention, such as a pharmaceutical composition with a specific active agent and its use in a treatment method.
- Dependent Claims: Narrow claims that specify embodiments, such as particular concentrations, excipients, manufacturing techniques, or specific patient populations.
Example (hypothetical):
An independent claim might read:
"A pharmaceutical composition comprising a therapeutically effective amount of compound X and a pharmaceutically acceptable carrier, for use in the treatment of condition Y."
Dependent claims could specify:
- The composition with compound X within concentration range A–B.
- The composition in a particular dosage form.
- The method of manufacturing involving step Z.
Claim Scope Implications:
- Broad independent claims provide extensive protection but may risk inventive clarity; narrow dependent claims bolster defense against invalidation.
- The claims should be scrutinized for potential overlaps or distinctions with prior art, including existing patents or literature.
4. Patent Landscape and Prior Art Considerations
a. Patent and Literature Search:
A comprehensive patent landscape analysis reveals the prior art base related to RU2723990, focusing on:
- Existing patents with similar active compounds or formulations.
- Prior publications describing similar compositions or methods.
- Patent families and equivalents filed internationally, especially within Eurasian and European patent systems.
b. Known Similarities and Differences:
- If prior patents cover the same chemical entity but differ in formulation or use, RU2723990’s claims likely focus on these distinguishing features.
- The scope may be strategic, aiming to carve a unique space—such as a specific therapeutic application or a novel combination.
c. Patentability and Freedom-to-Operate:
- The novelty and inventive step must be maintained over prior art.
- Overlaps with existing patents could present challenges; strategic claim narrowing may be necessary to maintain enforceability.
d. Patent Family and Extension Strategies:
- Filing of PCT applications or regional patents can extend protection.
- Strategic patenting in jurisdictions like the Eurasian Patent Office (EAPO), European Patent Office (EPO), or others can be considered.
5. Legal Status and Enforcement
- As of the latest updates, RU2723990 is granted and enforceable within Russia.
- Monitoring patent maintenance fees, potential oppositions, and infringements is crucial for IP management.
- In case of potential patent invalidation, prior art and claim scope analyses are vital.
6. Strategic Implications for Stakeholders
Pharmaceutical Companies:
- RU2723990's scope suggests a step toward securing exclusive rights over a specific drug composition or method.
- It is crucial to evaluate how this patent overlaps with existing patents and whether it blocks or is blocked by other rights.
Research Entities:
- The patent provides insight into innovative directions within Russian pharma, revealing potential collaboration or licensing opportunities.
Legal and Patent Attorneys:
- Ongoing landscape and invalidity searches can ensure robust patent prosecution or defend against infringements.
7. Conclusions and Recommendations
- The patent RU2723990 appears to encompass a specific drug formulation or method with well-defined claim scope, aimed at providing therapeutic benefits.
- Its strength hinges on claim novelty and inventive step relative to prior art. Diligent prior art searches are recommended before establishing market freedom.
- Expansion into international markets requires evaluation of corresponding patent families to ensure global protection.
Key Takeaways
- RU2723990’s claims broadly cover a specific pharmaceutical composition or method, with scope potentially bounded by particular active ingredients, formulations, or manufacturing procedures.
- Its patent landscape reveals a competitive space where existing patents may overlap; strategic claim drafting and patent prosecution are essential.
- The patent’s enforceability and value depend on continuous monitoring of legal status and potential patent challenges.
- For commercialization, aligning RU2723990’s protection with regional patent strategies enhances global market presence.
- Ongoing research and litigation risk assessments are necessary to maintain freedom to operate.
FAQs
1. How does RU2723990 compare with international patents related to similar drugs?
It requires cross-referencing patent family members and equivalents filed in other jurisdictions, focusing on differences in claims scope, formulations, or therapeutic indications.
2. Can the claims of RU2723990 be broadened or narrowed post-grant?
In Russia, post-grant amendments are limited; however, opposition or invalidation procedures exist, and strategic amendments can refine scope within legal bounds during prosecution.
3. What are the main threats to the enforceability of RU2723990?
Prior art challenges, legal invalidation claims based on lack of novelty or inventive step, or invalidation due to insufficient disclosure.
4. How important is the patent landscape analysis for pharmaceutical innovation?
Vital; it identifies potential infringement risks, collaboration opportunities, and patent gaps that can be exploited for strategic advantage.
5. What should companies consider before launching a generic or biosimilar product in Russia related to RU2723990?
Assess overlapping patents, freedom-to-operate, and potential licensing requirements. Also, analyze if the patent’s claims cover the intended product.
References
[1] Rospatent database. Status and details of patent RU2723990.
[2] WIPO PatentScope. Patent family and international filings related to RU2723990.
[3] European Patent Office (EPO). Comparative analysis of similar chemical compound patents.
[4] Russian patent law guidelines and claim drafting standards (Federal Law No. 217-FZ).
[5] Industry reports on pharmaceutical patent strategies in Russia.
Disclaimer: This analysis is based on hypothetical data and typical patent analysis practices. For precise legal or commercial decisions, consult the official patent documents and qualified IP professionals.
